CN102924629B - Enoxaparin sodium compound and preparation method thereof - Google Patents
Enoxaparin sodium compound and preparation method thereof Download PDFInfo
- Publication number
- CN102924629B CN102924629B CN2012105082530A CN201210508253A CN102924629B CN 102924629 B CN102924629 B CN 102924629B CN 2012105082530 A CN2012105082530 A CN 2012105082530A CN 201210508253 A CN201210508253 A CN 201210508253A CN 102924629 B CN102924629 B CN 102924629B
- Authority
- CN
- China
- Prior art keywords
- enoxaparin sodium
- sodium
- heparin
- quaternary ammonium
- ammonium salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides an enoxaparin sodium compound and a preparation method thereof. Liquaemin and benzethonium chloride are used as raw materials, sodium chloride is used as a neutral reaction medium and a microwave solid-phase synthesis method is carried out to prepare heparin quaternary ammonium salt.
Description
Technical field
The present invention relates to Enoxaparin Sodium and preparation method thereof, belong to medical technical field.
Background technology
Enoxaparin Sodium is a kind of novel antithrombotic reagent of being developed by French Sanofi-Aventis, obtains drugs approved by FDA in October, 2004.Thrombosis and treatment unstable angina pectoris and the non-Q ripple heart stalk etc. of extracorporeal circulation when Enoxaparin Sodium is used for prevention of deep vein thrombosis formation, prevention dvt formation and pulmonary infarction, the established deep venous thrombosis for the treatment of, preclude blood dialysis clinically, for present anticoagulation, antithrombotic first-selected medicine, the global marketing volume of 2006 reaches 24.35 Euros.
European Pharmacopoeia 5.3 editions is defined as follows enoxaparin: it is the low molecular weight heparin sodium that is generated by alkaline lysis by the heparin sodium that the chitling mucous membrane extracts obtains after esterification heparin benzyl ester sodio-derivative, it is comprised of the not qualitative oligose of many complexity, according to present understanding, most oligose has 4-enol pyrans saccharic acid at the non-reduced end of sugar chain, have 1,6-dehydrated structure in the reduction end of sugar chain and account for the 15%-25% of whole sugar.
The Enoxaparin Sodium weight-average molecular weight is between 3800-5000, and the oligose mass percent of molecular weight＜2000 is between 12%-20%, and the oligose mass percent of molecular weight 2000-8000 is at 68%-82%.By tiring at 90-125IU of every milligram of anti-Xa factor of dry product, the ratio of anti-Xa and anti-IIa is between 3.3-5.3.
The industrial method for preparing Enoxaparin Sodium mainly comprises the steps: at present
Chondroitin sulfate, dermatan sulfate in the first step, removal heparin sodium;
Second step, prepare the heparin quaternary ammonium salt;
The esterification of the 3rd step, heparin quaternary ammonium salt;
The 4th step, carboxylate obtain Enoxaparin Sodium through alkaline bleach liquor cleavage.
Prior art has been done more research for techniques such as the esterification yield in the Enoxaparin Sodium preparation process, the control that becomes the ring rate and product purifications, and for heparin sodium, become the technique of quaternary ammonium salt generally to adopt the method for US Patent No. 5389618: Teramine is dissolved in the water, join in the aqueous solution of removing the heparin sodium after impurity, produce water-fast multiple and salt, filtration is answered and salt, washes rear drying with water.
And the shortcoming of the method is to produce a large amount of contaminated wastewaters, and yield is lower simultaneously.In addition, the more important thing is, the moisture content of this step products heparin quaternary ammonium salt directly affects the height of the esterification yield of subsequent step.And research shows, esterification yield is higher, and the molecular-weight average of depolymerization product is lower, and when esterification yield was 12%-13%, the molecular weight of product just met the standard of European Pharmacopoeia 5.3 editions.And be difficult to accomplish the definitely anhydrous of product in existing technology.
For the defect of aforesaid method, the contriver, through large quantity research, becomes the technique of quaternary ammonium salt to improve to heparin sodium.
Summary of the invention
The purpose of this invention is to provide a kind of Enoxaparin Sodium, its structure is as follows:
Wherein, n=1-21, R=H or SO3Na, R1=H or SO3Na or COCH3, R2=H and R3=COONa, or R2=COONa and R3=H.
Another object of the present invention is to provide a kind of novel preparation method of Enoxaparin Sodium, be to provide specifically a kind of new synthetic process of heparin quaternary ammonium salt, more specifically, the solid phase synthesis process of heparin quaternary ammonium salt is provided, with overcome the yield that existing aqueous phase synthesis method exists low, produce a large amount of contaminated wastewaters, and affect the defect of subsequent step esterification yield.
Technical scheme of the present invention is: heparin sodium and benzethonium chloride are raw material,, take sodium-chlor as the neutral reaction medium, by the Microwave Solid synthetic method, prepare the heparin quaternary ammonium salt.
The preferred technical solution of the present invention is as follows:
1, heparin sodium is mixed with NaCl, benzyl rope chloramines;
2, mixture is placed in microwave reactor, with the power irradiation of 100-200W, temperature 40-80 ℃, irradiation time is 15-45min;
3, be cooled to room temperature, obtain the heparin quaternary ammonium salt;
4, the heparin quaternary ammonium salt obtains Enoxaparin Sodium through esterification, cracking.
Wherein the weight part of NaCl is 0.002-0.01, preferred 0.005 weight part;
Benzyl rope chloramines weight part is 1-2, preferred 1.5 weight parts;
The preferred 150W of microwave power;
The preferred 30min of microwave irradiating time;
Preferred 60 ℃ of microwave reaction temperature.
Method of the present invention has easy and simple to handle, and the reaction times is short, and yield is higher, does not produce waste water, has avoided simultaneously the moisture defect of product.
Embodiment
Be described in further detail by the following examples, but this should be interpreted as that scope of the present invention only limits to following examples, all technology that realizes based on technical scheme of the present invention all belong to scope of the present invention.
Embodiment 1
Taking heparin sodium 10g, sodium-chlor 50mg, benzyl rope chloramines 25g mixes, and is placed in microwave reactor, power 150W, after reacting 30min under temperature 60 C, the cooling heparin quaternary ammonium salt 30g that obtains;
Adopt the method for the method of US Patent No. 5389618, the heparin quaternary ammonium salt obtains enoxaparin 18.5g through esterification, cracking, purifying.
Product test is as follows:
Reference substance source: enoxaparin sodium injection (Ke Sai, the lot number: 110601-J), by Suzhou Erye Pharmaceutical Co., Ltd., press Enoxaparin Sodium feed purification method, extract refining of getting import.
One, high resolution mass spectrum
Mass spectrometer system: the LCMS-IT-TOF of Shimadzu company
The off-line positive ion mode, spray voltage 2.0kV, spraying gas velocity 0.5L/min, 200 ℃ of CDL temperature, 200 ℃ of heating module temperature, detector voltage 1.7kV, ion trap zone air pressure 2.4e-002Pa, TOF zone air pressure 1.8e-004Pa, 40 ℃ of TOF temperature.MS sweep limit: 200-1000m/z, ion accumulation time (Ion Accumulation Time) 20msec, multiplicity 2 times.
Reference substance and samples with water are dissolved to 5ug/ul.Regulating sample concentration with acetonitrile and formic acid is 2.5ug/ul.System is 50% acetonitrile/0.1 formic acid.All the other solution examples dilute one times with acetonitrile and formic acid, and mediation body is 50% acetonitrile/0.1 formic acid
1, molecular weight and distribution thereof
Measure by high resolution mass spectrum, according to m/z=(M+nH)/n formula to calculating molecular weight distribution, the molecular weight of the reference substance of Enoxaparin Sodium is from 226-2366, and the molecular weight analyte of Enoxaparin Sodium is from 273-2406, be normal distribution, molecular weight distribution both is basically identical.
2, the spectrum of the disaccharides after the hydrolysis, monose spectrum
In disaccharides spectrum, sample and reference substance all locate to have identical spectrum peak at m/z=226,301,362,378,453,498,675 etc.; And 301 and 453 places are the highest peak position; In the monose spectrum, sample and reference substance all have identical spectrum peak at m/z=149,205,279,280,391,445,588,668 places; And 149,205,391, locate to be relative highest peak position; Prompting sample and reference substance have essentially identical disaccharides spectrum after hydrolysis and the monose spectrum distributes.
Two, high performance liquid chromatography
Instrument title: Varian Prostar 500 high performance liquid chromatographs
Chromatographic column: 250mm*4.6mm SAX post Machery-Nagel company
Pre-column: 5mm*4.6mm SAX post Machery-Nagel company
Moving phase: (A) 0.28g/L potassium dihydrogen phosphate (pH=3)
(B) 140g/L sodium perchlorate solution (pH=3, with the preparation of pH=3 potassium dihydrogen phosphate)
Gradient: 0-40 minute A 97%-65% B 3%-35%
40-60 minute A 65%-50% B 35%-50%
60-70 minute A 50% B 50%
70-71 minute A 50%-97% B 50%-3%
71-90 minute A 97% B 3%
The HPLC result shows, the monose spectrum after trifluoroacetic acid hydrolysis, and the peak shape of reference substance and sample is basic identical, and the symmetry between 15-25 minute is better, confirms all to have in the product after reference substance and sample are hydrolyzed the existence of seminose.
Three, chromatography of ions
Ion chromatograph: DIONEX 500 ion chromatographs
Chromatographic column: PA-1 post
Detectability :≤0.02mg/L (Cl-)
Chromatography of ions detects and shows, the monose spectrum peak shape after the trifluoroacetic acid hydrolysis of enoxaparin sodium sample and reference substance is basic identical.
Four, comprehensive conclusion
Detect through high resolution mass spectrum, high performance liquid chromatography, chromatography of ions, carry out respectively heparinase hydrolysis and trifluoroacetic acid hydrolysis by the reference substance to Enoxaparin Sodium and sample, obtain both disaccharides spectrum and monose spectrum, compare by spectrogram, the sample of Enoxaparin Sodium and reference substance spectrogram structure are basic identical, and tentatively confirmatory sample forms basically identical with reference substance at monose and disaccharides structure.
Claims (1)
1. the preparation method of an Enoxaparin Sodium is characterized in that:
1) heparin sodium is mixed with NaCl, benzyl rope chloramines;
2) mixture is placed in microwave reactor, with the power irradiation of 100-200W, temperature 40-80 ℃, irradiation time is 15-45min;
3) be cooled to room temperature, obtain the heparin quaternary ammonium salt;
4) the heparin quaternary ammonium salt obtains Enoxaparin Sodium through esterification, cracking;
Wherein the weight part of NaCl is 0.005 weight part;
Benzyl rope chloramines weight part is the 1-2 weight part;
Microwave power is 150W;
Microwave irradiating time is 30min;
The microwave reaction temperature is 60 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105082530A CN102924629B (en) | 2012-12-03 | 2012-12-03 | Enoxaparin sodium compound and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105082530A CN102924629B (en) | 2012-12-03 | 2012-12-03 | Enoxaparin sodium compound and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102924629A CN102924629A (en) | 2013-02-13 |
| CN102924629B true CN102924629B (en) | 2013-11-13 |
Family
ID=47639573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012105082530A Active CN102924629B (en) | 2012-12-03 | 2012-12-03 | Enoxaparin sodium compound and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102924629B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104086674B (en) * | 2014-07-28 | 2016-08-17 | 常州千红生化制药股份有限公司 | A kind of technique preparing Enoxaparin Sodium |
| CN111670204B (en) | 2017-12-11 | 2022-07-29 | 生物E有限公司 | Process for preparing low molecular weight heparin |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1850865A (en) * | 2006-05-24 | 2006-10-25 | 杭州九源基因工程有限公司 | Production method for purifying enoxaparin sodium |
| CN101165071A (en) * | 2006-10-20 | 2008-04-23 | 江苏江山制药有限公司 | Clexane and preparation method thereof |
-
2012
- 2012-12-03 CN CN2012105082530A patent/CN102924629B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1850865A (en) * | 2006-05-24 | 2006-10-25 | 杭州九源基因工程有限公司 | Production method for purifying enoxaparin sodium |
| CN101165071A (en) * | 2006-10-20 | 2008-04-23 | 江苏江山制药有限公司 | Clexane and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102924629A (en) | 2013-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0027089B1 (en) | Oligosaccharide fractions and oligosaccharides with biological properties, process for their preparation and their uses as medicines | |
| Ingle et al. | A world of low molecular weight heparins (LMWHs) enoxaparin as a promising moiety—A review | |
| JP4594298B2 (en) | High purity fondaparinux sodium composition | |
| Wang et al. | Molecular weight-dependent anticoagulation activity of sulfated cellulose derivatives | |
| EP2697265B1 (en) | Polysaccharides comprising two antithrombin iii-binding sites, preparation thereof and use thereof as antithrombotic medicaments | |
| Wang et al. | Liquid chromatography–diode array detection–mass spectrometry for compositional analysis of low molecular weight heparins | |
| EP2427503B1 (en) | Novel acylated decasaccharides and their use as antithrombotic agents | |
| CN104558252A (en) | Method for producing enoxaparin sodium by using crude sodium heparin products | |
| CN103675144B (en) | Method for chemically degrading heparin and detecting composition of heparin disaccharide | |
| CN102924629B (en) | Enoxaparin sodium compound and preparation method thereof | |
| RU2670767C1 (en) | Method for producing low molecular weight heparin | |
| CN101605549A (en) | The heparin, its preparation and the purposes that comprise the covalent bond of at least one and biotin or biotin derivative | |
| US20120108542A1 (en) | Sulfated octasaccharide and its use as antithrombotic agent | |
| EP2980103B1 (en) | Low molecular weight glycosaminoglycan derivative, pharmaceutical composition thereof, preparation method therefor and use thereof | |
| Figueiredo et al. | Monitoring of κ-carrageenan depolymerization by capillary electrophoresis and semisynthesis of oligosaccharide alditols | |
| CN110174474A (en) | The detection method of L MALIC ACID isomers in Multiple electrolytes injection (II) | |
| CN109485749A (en) | A method of chromatography and Ultrafiltration Membrane prepare Enoxaparin Sodium | |
| Larnkjaer et al. | Isolation and charaterization of hexasaccharides derived from heparin. Analysis by HPLC and elucidation of structure by 1H NMR | |
| CN106977627A (en) | A kind of Enoxaparin production method of sodium | |
| WO2010128446A1 (en) | Novel acylated 1,6-anhydro decasaccharide and its use as antithrombotic agent | |
| CN111154012A (en) | Preparation method of ultra-high purity heparan sulfate | |
| Zhang-Run et al. | Heparinase digestion-based disaccharide composition analysis of heparin and heparinoid drugs | |
| CN110698522B (en) | Odd-numbered chondroitin oligosaccharide monomer and preparation method and application thereof | |
| CN104914205A (en) | Segregation analysis method for heparan disaccharide sulfate containing FlcNH3<+> | |
| CN105399870A (en) | Low anticoagulant heparin and oligosaccharides thereof, and preparation methods and application of low anticoagulant heparin and oligosaccharides thereof in preparation of anti-Alzheimer's disease drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |